Buprenorphine: A New Treatment for Opioid Dependence Part 1
For more information on this and other stories, visit www.newsinfusion.com Taking strong opioid painkillers, in large doses, for an extended ...
TheraQuest Unveils New Pain Management Product Pipeline
/PRNewswire/ -- TheraQuest Biosciences, Inc., a clinical stage pain management company today unveiled its analgesic product pipeline. TheraQuest also announced the launch of its new corporate website at http://www.theraquestinc.com .Najib Babul, PharmD, President and Chief Executive Officer, said, "After a careful strategic review of our pipeline, we have realigned our development efforts to focus on chronic pain products with the largest market potential and greatest probability for timely FDA approval." Babul further noted, "Going forward, we will focus our development resources on drugs to treat chronic musculoskeletal conditions such as osteoarthritis and low back pain, and on neuropathic pain."
Overview of Pain Pipeline
TQ-1020 (Levorphanol Extended Release) is a proprietary once-a-day extended release levorphanol in an abuse deterrent drug delivery system. It has activity at both opioid and non-opioid receptors and monoamine reuptake inhibition comparable to Nucynta® and Ultram®.
Opioid treatment tramadol buprenorphine - News
|
TheraQuest Unveils New Pain Management Product Pipeline TQ-1028 is a proprietary once-a-day extended release oral dosage form of the C-III opioid, buprenorphine. It is being developed for the treatment of chronic |
|
Report: Drugs found in dead people's bodies Buprenorphine, Fentanyl, Heroin, Hydrocodone, Hydromorphone, Meperidine, Methadone, Morphine, Oxycodone, Oxymorphone, Propoxyphene, and Tramadol. |